Propiedad y actividad de insiders de Inhibrx Biosciences Inc. (INBX): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $101.77 |
| Capitalización | $1.5B |
| Bolsa | NASDAQ |
| País | US |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $20.0M | $13.5M | $2.1M | $11.5M | $128.7M | $131.3M | $273.9M | $277.9M | $152.6M | $124.2M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | $696000 | $690000 | $438000 | $615000 | $878000 | $257000 | $778000 | $420000 | $177000 |
| Inventario | 0 | $999000 | $2.3M | $3.2M | -$129.3M | -$878000 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $20.4M | $15.4M | $5.7M | $15.6M | $132.2M | $139.1M | $280.5M | $295.4M | $160.4M | $132.8M |
| Inmovilizado Material | $864000 | $1.8M | $2.6M | $10.7M | $11.3M | $9.5M | $7.2M | $9.4M | $13.5M | $9.3M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $21.3M | $17.2M | $10.0M | $26.5M | $143.7M | $150.4M | $290.9M | $307.9M | $180.8M | $146.5M |
| Cuentas por Pagar | $167000 | $775000 | $6.5M | $3.1M | $13.5M | $9.1M | $8.3M | $11.0M | $9.2M | $5.9M |
| Deuda a Corto | $4.3M | $5.2M | $5.9M | $4.7M | $1.5M | $1.7M | $1.9M | 0 | $1.6M | $2.3M |
| Pasivos Corrientes | $5.3M | $8.9M | $16.2M | $20.6M | $31.4M | $22.5M | $27.6M | $56.3M | $40.7M | $33.8M |
| Deuda a Largo | $14.7M | $9.5M | $3.6M | $37.1M | $36.0M | $70.5M | $202.1M | $207.0M | 0 | $100.6M |
| Pasivos Totales | $20.0M | $39.7M | $67.6M | $120.1M | $68.3M | $98.1M | $232.8M | $264.4M | $47.2M | $138.5M |
| Reservas | -$9.2M | -$28.8M | -$17.9M | -$69.3M | -$145.4M | -$227.1M | -$372.4M | -$613.7M | -$106.1M | -$246.2M |
| Patrimonio Neto | -$9.2M | -$28.8M | -$57.6M | -$93.6M | $75.5M | $52.4M | $58.1M | $43.5M | $133.6M | $8.0M |
| Deuda Total | $18.9M | $14.7M | $9.5M | $41.7M | $37.5M | $72.1M | $207.1M | $210.1M | $8.0M | $107.0M |
| Deuda Neta | -$1.1M | $1.2M | $7.4M | $30.2M | -$91.2M | -$59.2M | -$66.8M | -$67.8M | -$144.5M | -$17.2M |
| Capital Circulante | $15.1M | $6.5M | -$10.5M | -$5.0M | $100.8M | $116.7M | $252.9M | $239.0M | $119.7M | $99.0M |
Salud financiera
| Deuda / Patrimonio | -0.10 |
| Ratio corriente | 5.07 |
Rentabilidad
| Rentabilidad sobre capital | 1893.60% |
| Rentabilidad sobre capital invertido | -99.35% |
| Rentabilidad sobre activos | -89.60% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Empresas relacionadas: AMLX · ATAI · CVAC · ELVN · IMTX · NKTR · ORIC
Explorar sector: Healthcare · Biotechnology
Más secciones de INBX: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones